U.S. Markets close in 4 hrs 19 mins

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018

PARIS and TARRYTOWN, N.Y., May 16, 2018 /PRNewswire/ -- A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints. In the trial, treatment with Dupixent as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures. Dupixent is the first and only biologic to show positive results in this patient population.

"Moderate-to-severe atopic dermatitis can place a particularly significant burden on adolescents, who have to deal with oozing skin lesions with unrelenting, intense itching during their formative years," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron. "Dupixent blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation. We are committed to investigating the potential for Dupixent across Type 2 inflammatory diseases with high unmet need including atopic dermatitis, asthma, eosinophilic esophagitis, nasal polyps, chronic obstructive pulmonary disease, and food allergy."

Patients treated with Dupixent had significant improvement in disease severity at 16 weeks

The primary endpoints were the proportion of patients achieving Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) and 75% improvement in Eczema Area and Severity Index (EASI-75, co-primary endpoint outside of the U.S.) at 16 weeks. Results included:

  • 24% of patients who received weight-based dosing of Dupixent every two weeks (200 mg or 300 mg) and 18% of patients who received a fixed dose of Dupixent every four weeks (300 mg) achieved the primary endpoint – clear or almost-clear skin (IGA; score of 0 or 1) – compared with 2% with placebo (p less than 0.0001, and p=0.0007, respectively).
  • 41.5% of patients who received Dupixent every two weeks and 38% of patients who received Dupixent every four weeks achieved 75% or greater skin improvement (EASI-75) compared to 8% with placebo (p less than 0.0001).
  • There was a 66% improvement in the Dupixent every two weeks group and, 65% improvement in the Dupixent every four weeks group in average percent change from baseline in EASI score compared with a 24% improvement in the placebo group (p less than 0.0001).
  • There was a 48% improvement in the Dupixent every two weeks group and 45.5% improvement in the Dupixent every four weeks group in average percent change from baseline in the pruritus numerical rating scale (NRS) compared with a 19% improvement in the placebo group (p less than 0.0001).

"Current treatment options for these adolescent patients such as topical steroids, oral steroids, and non-steroidal immunosuppressants can have significant side effects," said Elias Zerhouni, M.D., President, Global R&D, Sanofi. "We continue to explore Dupixent's role in targeting Type 2 inflammation as an underlying cause of atopic dermatitis to potentially provide adolescents, some of whom have lived with this disease their entire lives, a therapy that treats more than just their symptoms."

Dupixent safety profile was consistent with that seen in adults

For the 16-week treatment period, the overall rate of adverse events was comparable between the Dupixent groups and placebo (72% for Dupixent every two weeks, 64% for Dupixent every four weeks and 69% for placebo). There were no serious adverse events or events leading to treatment discontinuation in either Dupixent treatment group.

Adverse events that were observed at a higher rate with Dupixent included injection site reactions (8.5% for Dupixent every two weeks, 6% for Dupixent every four weeks compared with 3.5% for placebo) and conjunctivitis (10% for Dupixent every two weeks, 11% for Dupixent every four weeks compared with 5% for placebo). Skin infections were numerically lower in the Dupixent groups (11% for Dupixent every two weeks, 13% for Dupixent every four weeks compared with 20% for placebo).  

Detailed results from this trial will be presented at a future medical meeting. These data will be submitted to regulatory authorities later this year.  In 2016, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Dupixent for the treatment of moderate-to-severe (12 to 17 years of age) and severe (6 months to 11 years of age) atopic dermatitis.

The safety and efficacy of Dupixent in the adolescent atopic dermatitis population have not been fully evaluated by any regulatory authority.

About the Dupixent Trial in Adolescent Patients

The pivotal, Phase 3, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent monotherapy in adolescent patients with moderate-to-severe atopic dermatitis. The trial enrolled 251 patients who were 12 years to 17 years of age with moderate-to-severe atopic dermatitis whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable. In total, 92% of these patients suffered from at least one concurrent allergic condition such as allergic rhinitis, asthma or food allergy.

The primary endpoint of this trial was the proportion of patients with an IGA score of 0 or 1 at Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) that measures overall severity of skin lesions. A co-primary endpoint outside of the U.S. and a key secondary endpoint in the U.S. was the proportion of patients who achieved 75% or greater skin improvement as measured by the EASI-75 at Week 16. EASI is a tool used to measure the extent and severity of the disease.

Patients were randomized into one of three treatment groups for the controlled period of 16 weeks: the first group was treated with Dupixent subcutaneous injection 200 mg or 300 mg every two weeks, based on weight (with an initial dose of 400 mg or 600 mg respectively). The second group was treated with 300 mg Dupixent every four weeks (with an initial dose of 600 mg), and the third group was treated with placebo every two weeks.

About Moderate-to-Severe Atopic Dermatitis

Atopic dermatitis, a form of eczema, is a chronic inflammatory disease with symptoms often appearing as a rash on the skin.i,ii,iii,iv Moderate-to-severe atopic dermatitis is characterized by rashes often covering much of the body, and can include intense, persistent itching and skin dryness, cracking, redness, crusting, and oozing.v Itch is one of the most burdensome symptoms for patients and can be debilitating.vi In addition, patients with moderate-to-severe atopic dermatitis experience a substantial burden of disease, including painful skin lesions and intense pruritus.6

Dupilumab Development Program

Sanofi and Regeneron are studying dupilumab in a broad range of clinical development programs for diseases driven by Type 2 inflammation, including asthma (Phase 3), pediatric atopic dermatitis (Phase 3, ages 6 months - 11 years), nasal polyps (Phase 3) and eosinophilic esophagitis (Phase 2). Future trials are planned for chronic obstructive pulmonary disease, grass allergy and food allergy (including peanut). These potential uses are investigational and the safety and efficacy have not been evaluated by any regulatory authority. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

For more information on dupilumab clinical trials please visit www.clinicaltrials.gov.

About Dupixent® (dupilumab)

Dupixent is currently approved in the U.S. for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Dupixent is also approved for use in certain patients with moderate-to-severe atopic dermatitis in a number of other countries, including the countries of the European Union, Canada, and Japan. The safety and efficacy of Dupixent in the adolescent atopic dermatitis population have not been fully evaluated by any regulatory authority.

In addition, the potential use of Dupixent for the treatment of certain adults and adolescents with inadequately controlled moderate-to-severe asthma is currently under regulatory review in the U.S. and European Union, and the safety and efficacy for this use have not been fully evaluated by any regulatory authority.

IMPORTANT SAFETY INFORMATION AND INDICATION

Do not use if you are allergic to dupilumab or to any of the ingredients in Dupixent.

Before using Dupixent, tell your healthcare provider about all your medical conditions, including if you:

  • have eye problems
  • have a parasitic (helminth) infection
  • have asthma
  • are scheduled to receive any vaccinations. You should not receive a "live vaccine" if you are treated with Dupixent.
  • are pregnant or plan to become pregnant. It is not known whether Dupixent will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known whether Dupixent passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. If you have asthma and are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider.

Dupixent can cause serious side effects, including:

  • Allergic reactions. Stop using Dupixent and go to the nearest hospital emergency room if you get any of the following symptoms: fever, general ill feeling, swollen lymph nodes, hives, itching, joint pain, or skin rash.
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision.

The most common side effects include injection site reactions, eye and eyelid inflammation, including redness, swelling and itching, and cold sores in your mouth or on your lips.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Dupixent. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Use Dupixent exactly as prescribed. If your healthcare provider decides that you or a caregiver can give Dupixent injections, you or your caregiver should receive training on the right way to prepare and inject Dupixent. Do not try to inject Dupixent until you have been shown the right way by your healthcare provider.

Please click here for the full Prescribing Information. The patient information is available here.

INDICATION

Dupixent is used to treat adult patients with moderate-to-severe atopic dermatitis (eczema) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. Dupixent can be used with or without topical corticosteroids. It is not known if Dupixent is safe and effective in children. Dupixent is administered by subcutaneous injection at different injection sites every two weeks after an initial loading dose. Dupixent is intended for use under the guidance of a healthcare provider. A patient may self-inject Dupixent after training in subcutaneous injection technique using the pre-filled syringe. 

About Sanofi

Sanofi (NYSE: SNY; EURONEXT: SAN) is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

About Regeneron Pharmaceuticals, Inc

Regeneron (REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Sanofi Media Relations Contact

Investor Relations Contact

Ashleigh Koss

George Grofik

Tel.: +1 908-981-8745

Tel.: +33 (0)1 53 77 45 45

mr@sanofi.com

ir@sanofi.com



Regeneron Media Relations

Regeneron Investor Relations Contact

Contact

Manisha Narasimhan, Ph.D.

Sharon Chen

Tel: +1 914-847-5126

Tel.: +1 914-847-1546

Manisha.narasimhan@regeneron.com

sharon.chen@regeneron.com


Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements and Use of Digital Media
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) Injection; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, such as dupilumab for the treatment of moderate-to-severe atopic dermatitis in adolescents, pediatric atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease, grass allergy, food allergy, and other potential indications; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in later studies and lead to therapeutic applications; unforeseen safety issues and possible liability resulting from the administration of products and product candidates in patients, including without limitation dupilumab; serious complications or side effects in connection with the use of Regeneron's products and product candidates (such as dupilumab) in clinical trials; coverage and reimbursement determinations by third-party payers, including Medicare, Medicaid, and pharmacy benefit management companies; ongoing regulatory obligations and oversight impacting Regeneron's marketed products, research and clinical programs, and business, including those relating to the enrollment, completion, and meeting of the relevant endpoints of post-approval studies; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates, such as Dupixent; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation proceedings relating to Praluent® (alirocumab) Injection, the ultimate outcome of any such litigation proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the quarterly period ended March 31, 2018. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).

_____________________________
i Eichenfield et al. Guidelines of Care for Atopic Dermatitis. AAD 2014, pp. 118.
ii Guideline to treatment, European Dermatology Forum. http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous?download=36:guideline-treatment-of-atopic-eczema-atopic-dermatitis. Accessed December 23, 2016.
iii Gelmetti and Wolleberg, BJD 2014, Atopic dermatitis- all you can do from the outside. Page 19.
iv National Institutes of Health (NIH). Handout on Health: Atopic Dermatitis (A type of eczema) 2013. http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp. Accessed October 31, 2016.
v Mount Sinai. Patient Care Atopic Dermatitis. Available at: http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/atopic-dermatitis#risk. Accessed August 2017.
vi Zuberbier T et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol vol. 118, pp. 226-232, 2006.

 

Cision

View original content:http://www.prnewswire.com/news-releases/dupixent-dupilumab-showed-positive-phase-3-results-in-adolescents-with-inadequately-controlled-moderate-to-severe-atopic-dermatitis-300649146.html

  • Business
    Motley Fool

    What You Need to Know Before Buying Nintendo Stock

    Nintendo (NASDAQOTH: NTDOY) may own some of the most recognizable intellectual property in video games, but the stock is not as closely followed as its American peers. Here's a look at how you can become a Nintendo investor and what resources are available to learn more about its business.

  • Here’s why you shouldn’t retire super early — even if you can
    Business
    MarketWatch

    Here’s why you shouldn’t retire super early — even if you can

    Despite the many perks of early retirement — waking up whenever you want, for example — it wasn’t the easiest decision. Earnings tend to peak around 48 for men and about 39 for women, according to an analysis by PayScale.

  • Business
    Benzinga

    Jim Cramer Shares His Thoughts On Amarin, AT&T, McDonald's And More

    On CNBC's "Mad Money Lightning Round", Jim Cramer said Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is a great speculative stock. Cramer is willing to endorse AT&T Inc. (NYSE: T), but he thinks Verizon Communications Inc. (NYSE: VZ) offers more safety

  • Goldman Sachs Adds Nvidia To 'Conviction Buy' List
    Business
    Yahoo Finance Video

    Goldman Sachs Adds Nvidia To 'Conviction Buy' List

    Goldman Sachs analyst Toshiya Hari reiterated his 'Buy' rating for Nvidia and added the chip-maker to Goldman’s 'Conviction Buy' list.

  • What happens if you win Mega Millions' $970M jackpot?
    News
    Associated Press

    What happens if you win Mega Millions' $970M jackpot?

    Despite the terrible odds — one in 302.5 million for those keeping score at home — someone will eventually match all six numbers and win the Mega Millions jackpot, which now stands at $970 million. Here are some answers for someone holding that prized lottery ticket for what would be the second-largest lottery jackpot in U.S. history. Lottery officials recommend winners take a deep breath, put their winning ticket in a safe spot and consult with a reputable financial planner before popping over to the lottery headquarters.

  • It’s a ‘Hold’ for Nokia: A Look at Analyst Recommendations
    Finance
    Market Realist

    It’s a ‘Hold’ for Nokia: A Look at Analyst Recommendations

    Nokia in Q3 2018: Why Analysts Are Estimating Lower (Continued from Prior Part) Stock up 23% in 2018 Nokia (NOK) stock fell 32% in 2016 and traded flat in 2017. Since the start of 2018, however, it has risen ~23%. It has fallen 5% in the last 12 months

  • Why Western Digital Stock Declined 28.4% in 2018
    Finance
    Market Realist

    Why Western Digital Stock Declined 28.4% in 2018

    What Do Analysts Expect from Western Digital in Q1 2019? (Continued from Prior Part) WDC stock down 28.4% this year Semiconductor company Western Digital’s (WDC) stock price has declined 28.4% year-to-date. The stock is trading 48.0% below its 52-week

  • Ford CEO seeks to rally dealers as shares sink to new low
    Business
    Reuters

    Ford CEO seeks to rally dealers as shares sink to new low

    With Ford Motor Co's stock at nearly a nine-year low and the company squeezed by tariffs and trade tensions, Chief Executive Jim Hackett sought to restore confidence among dealers gathered in Las Vegas this week, days ahead of announcing the automaker's third-quarter results. In closed-door meetings with members of Ford's national dealer network, Hackett and other top Ford executives showed off future versions of the popular Explorer and Escape SUVs, as well as new the Ranger mid-sized pickup truck and an unnamed smaller off-road utility vehicle, attendees said. Ford has said it will refresh 75 percent of its North American lineup over the next two years.

  • Finance
    InvestorPlace

    YY Stock Has Become a Bargain, But Don’t But It Yet!

    YY Inc. (NASDAQ:YY) continues to fall, even as the Chinese, video-based social media company increases its profits. The YY stock price has now dropped by more than 55% since achieving its 52-week high in January. The possible geopolitical and industry risk may deter investors from buying YY stock.

  • Why Yandex N.V. Stock Plunged Today
    Business
    Motley Fool

    Why Yandex N.V. Stock Plunged Today

    What happened Shares of Yandex N.V. (NASDAQ: YNDX) dropped 17.8% on Thursday following reports that Russia's state-owned Sberbank may take a controlling stake in the country's leading internet search company. More specifically, according to sources speaking

  • Is CenturyLink, Inc. a Buy?
    Business
    Motley Fool

    Is CenturyLink, Inc. a Buy?

    Legacy landline telecom CenturyLink, Inc. (NYSE: CTL) gets plenty of grief. And understandably so, considering that its legacy business, copper wire landline and internet connections is a steadily declining business while fiber and wireless technologies

  • Palo Alto Networks Stock Upgraded: What You Need to Know
    Business
    Motley Fool

    Palo Alto Networks Stock Upgraded: What You Need to Know

    Cybersecurity company Palo Alto Networks (NYSE: PANW) won a big upgrade today when analysts at R.W. Baird announced they're assuming coverage of the stock and raising their price target to $250 a share. If they're right about that, Palo Alto Networks is worth more than 23% more than it currently costs. Many companies offer cybersecurity services, but which one is the best to invest in?

  • Love Dividends? 3 Stocks You Might Want to Buy
    Business
    Motley Fool

    Love Dividends? 3 Stocks You Might Want to Buy

    It's even better when you know that the dividend is a big one! You'll get more of those good feelings if you add high-yielding Magellan Midstream Partners, L.P. (NYSE: MMP), General Mills, Inc. (NYSE: GIS), and Tanger Factory Outlet Centers, Inc. (NYSE: SKT) to your income portfolio. It has also been reworking older brands, notably with new yogurt and ice cream products.

  • What Drove Kinder Morgan’s Q3 Distributable Cash Flow?
    Finance
    Market Realist

    What Drove Kinder Morgan’s Q3 Distributable Cash Flow?

    Decoding Kinder Morgan's Third-Quarter Earnings Kinder Morgan’s DCF Kinder Morgan (KMI) reported its third-quarter results on October 17. Kinder Morgan’s DCF (distributable cash flow) in the third quarter rose ~3.6% YoY (year-over-year) to $1.093

  • Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight
    Politics
    Time

    Provocateur Stormy Daniels Takes an Unexpected Turn in the National Spotlight

    To understand what it means to be famous like Stormy Daniels, for the reasons she is famous, spend time with her in a public space. On Oct. 15, a California judge threw out the defamation case she filed against Donald Trump. Over the past year, Daniels, 39, has become the Zelig of White House scandals.

  • Amex posts beat, PayPal shines, Ford makes moves
    Finance
    Yahoo Finance

    Amex posts beat, PayPal shines, Ford makes moves

    American Express beat expectations in its latest earnings. Profit was up 22% last quarter and Amex says it expects full year revenue to rise upwards of 10%. The company also says it just signed a deal to let customers pay their bills through PayPal. Speaking of PayPal, it also posted a big beat in its latest earnings report. A surge in payment volume for Venmo helped boost the bottom line, with overall revenue up 14%. PayPal says it added a record $9.1M accounts in the third quarter.

  • Home Depot vs. Lowe’s: Both Stocks Are Slumping, So Which One Should You Buy?
    Finance
    GoBankingRates

    Home Depot vs. Lowe’s: Both Stocks Are Slumping, So Which One Should You Buy?

    An analyst downgrade based on housing market outlooks has sent stocks from Lowe’s and Home Depot down over the last two days. Both Home Depot and Lowe’s are in downtrends dating back to September. On Wednesday, shares in Lowe’s and The Home Depot were slumping after disappointing housing market data led a key analyst to downgrade his ratings and slash price targets, and both stocks continued the slump into a second day on Thursday.

  • Tesla unveils 'lower-cost' Model 3
    Business
    Yahoo Finance Video

    Tesla unveils 'lower-cost' Model 3

    Elon Musk rolled out what he called the "lower-cost, mid-range" Model 3, on Twitter. Yahoo Finance's Alexis Christoforous, Rick Newman and Dan Roberts break down the details.

  • Better Buy: GlaxoSmithKline plc vs. Eli Lilly
    Business
    Motley Fool

    Better Buy: GlaxoSmithKline plc vs. Eli Lilly

    People get sick regardless of the economic cycle, so companies that cater to healing them often outperform during downturns, and their stocks are considered "defensive." Healthy and dependable dividends can also contribute to stabilizing portfolio returns in good times and bad. Two successful blue-chip stocks in the healthcare industry are British GlaxoSmithKline plc (NYSE: GSK) and Eli Lilly (NYSE: LLY). Investors like both stocks for their dividends and consistent performance, but the companies are really quite different, with GlaxoSmithKline diversified into vaccines and consumer products, and Eli Lilly focused on pharmaceuticals.

  • American Electric Power: Analysts’ Recommendations
    Finance
    Market Realist

    American Electric Power: Analysts’ Recommendations

    Analyzing AEP’s Performance before its Q3 2018 Earnings (Continued from Prior Part) Analysts’ recommendations As of October 17, Reuters compiled data from 19 analysts tracking American Electric Power Company (AEP) stock. Five analysts recommended a “

  • Business
    TheStreet.com

    Micron Buying Out Intel's Stake in Flash Memory Joint Venture for $1.5 Billion

    The venture produces 3D XPoint flash memory, which Micron says is 1,000 times faster than NAND memory. Micron CEO Sanjay Mehrotra predicted that the technology will be an "essential solution for new data-hungry applications," in a press release announcing the deal. Shares of Micron gained 0.4% to $41.48 Thursday morning, while Intel was flat at $44.97.

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.

  • Business
    Bloomberg

    Sears Burns Cash While Betting on Lampert Loans for Survival

    Sears is expected to bleed $220 million in just the first month of its bankruptcy, court filings show, cutting deep into the $300 million loan it secured this week from senior lenders. The crunch could become more acute if Sears doesn’t get an additional $300 million it’s counting on from Chairman Eddie Lampert to keep operating beyond the next 15 days. The retailer is staking its turnaround on getting a $112 million loan from Lampert’s ESL Investments hedge fund by Nov. 3, according to a budget approved by the court, and another $188 million over the following two months.

  • Turkish Official Says Jamal Khashoggi's Remains May Have Been Taken Outside Istanbul
    World
    Time

    Turkish Official Says Jamal Khashoggi's Remains May Have Been Taken Outside Istanbul

    The official told The Associated Press that police have established that two vehicles belonging to the consulate, left the building on Oct. 2 — the day Khashoggi had walked into the consulate and vanished. One of the vehicles traveled to the nearby Belgrade Forest while the other traveled to the city of Yalova, across the Sea of Marmara from Istanbul, the official said, speaking on condition of anonymity due to the secrecy of the ongoing investigation. Turkish reports say Khashoggi was brutally murdered and dismembered inside the consulate by members of an assassination squad with ties to Saudi Crown Prince Mohammed bin Salman.

  • Why Activision Blizzard, United Rentals, and Gap Slumped Today
    Business
    Motley Fool

    Why Activision Blizzard, United Rentals, and Gap Slumped Today

    The stock market had a tough session on Thursday, with the Dow Jones Industrial Average finishing down over 300 points. Investors continued to worry about rising interest rates in the U.S., but they also turned their attention to the global macroeconomic picture, where new concerns about the prospects for growth in areas like Europe and China weighed on sentiment. Company-specific news hurt certain stocks, and Activision Blizzard (NASDAQ: ATVI), United Rentals (NYSE: URI), and Gap (NYSE: GPS) were among the worst performers on the day.